News, Media & Events

July 14th, 2010

ChemGenex and U.S. FDA Agree on Potential Regulatory Pathway for OMAPRO™

· Company will submit new NDA in CML patients who have failed multiple TKIs
· Investor Teleconference to be held today - Wednesday 14th July 10.30am AEST / Tuesday 13th July 5.30pm PDT

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (14 July 2010) – ChemGenex Pharmaceuticals Limited (ASX: CXS) announced today it has agreed [...]

June 7th, 2010

ChemGenex Announces Positive Safety Data on OMAPRO™ Presented at ASCO

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (7 June 2010) – ChemGenex Pharmaceuticals Limited (ASX: CXS) announced that positive safety findings from a combined analysis of two clinical trials for its lead product candidate, OMAPRO™ (omacetaxine mepesuccinate), were presented today during a poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual [...]